tetano
Editor, Senior Moderator
Front Immunol
. 2023 May 17;14:1166261.
doi: 10.3389/fimmu.2023.1166261. eCollection 2023. Analysis and comparison of SARS-CoV-2 variant antibodies and neutralizing activity for 6 months after a booster mRNA vaccine in a healthcare worker population
Sina Hosseinian[SUP] 1 [/SUP], Rafael de Assis[SUP] 2 [/SUP], Ghali Khalil[SUP] 1 [/SUP], Madeleine K Luu[SUP] 3 [/SUP], Aarti Jain[SUP] 2 [/SUP], Peter Horvath[SUP] 4 [/SUP], Rie Nakajima[SUP] 2 [/SUP], Anton M Palma[SUP] 4 [/SUP], Anthony Hoang[SUP] 3 [/SUP], Eisa Razzak[SUP] 3 [/SUP], Nicholas Garcia[SUP] 1 [/SUP], Joshua Alger[SUP] 4 [/SUP], Mina Kalantari[SUP] 5 [/SUP], Emily K Silzel[SUP] 2 [/SUP], Algis Jasinskas[SUP] 2 [/SUP], Frank Zaldivar[SUP] 2 6 [/SUP], Sebastian D Schubl[SUP] 7 [/SUP], Philip L Felgner[SUP] 2 [/SUP], Saahir Khan[SUP] 8 [/SUP]
Affiliations
Introduction: In the context of recurrent surges of SARS-CoV-2 infections, a detailed characterization of antibody persistence over a 6-month period following vaccine booster dose is necessary to crafting effective public health policies on repeat vaccination.
Methods: To characterize the SARS-CoV-2 antibody profile of a healthcare worker population over a 6-month period following mRNA vaccination and booster dose. 323 healthcare workers at an academic medical center in Orange County, California who had completed primary vaccination and booster dose against SARS-CoV-2 were recruited for the study. A total of 690 blood specimens over a 6-month period were collected via finger-stick blood and analyzed for the presence of antibodies against 9 SARS-CoV-2 antigens using a coronavirus antigen microarray.
Results: The primary outcome of this study was the average SARS-CoV-2 antibody level as measured using a novel coronavirus antigen microarray. Additional outcomes measured include levels of antibodies specific to SARS-CoV-2 variants including Delta, Omicron BA.1, and BA.2. We also measured SARS-CoV-2 neutralization capacity for a subset of the population to confirm correlation with antibody levels. Although antibodies against SARS-CoV-2 wane throughout the 6-month period following a booster dose, antibody levels remain higher than pre-boost levels. However, a booster dose of vaccine based on the original Wuhan strain generates approximately 3-fold lower antibody reactivity against Omicron variants BA.1 and BA.2 as compared to the vaccine strain. Despite waning antibody levels, neutralization activity against the vaccine strain is maintained throughout the 6-month period.
Discussion: In the context of recurrent surges of SARS-CoV-2 infections, our data indicate that breakthrough infections are likely driven by novel variants with different antibody specificity and not by time since last dose of vaccination, indicating that development of vaccinations specific to these novel variants is necessary to prevent future surges of SARS-CoV-2 infections.
Keywords: SARS-CoV-2; healthcare worker (HCW); mRNA; serology; vaccine.
. 2023 May 17;14:1166261.
doi: 10.3389/fimmu.2023.1166261. eCollection 2023. Analysis and comparison of SARS-CoV-2 variant antibodies and neutralizing activity for 6 months after a booster mRNA vaccine in a healthcare worker population
Sina Hosseinian[SUP] 1 [/SUP], Rafael de Assis[SUP] 2 [/SUP], Ghali Khalil[SUP] 1 [/SUP], Madeleine K Luu[SUP] 3 [/SUP], Aarti Jain[SUP] 2 [/SUP], Peter Horvath[SUP] 4 [/SUP], Rie Nakajima[SUP] 2 [/SUP], Anton M Palma[SUP] 4 [/SUP], Anthony Hoang[SUP] 3 [/SUP], Eisa Razzak[SUP] 3 [/SUP], Nicholas Garcia[SUP] 1 [/SUP], Joshua Alger[SUP] 4 [/SUP], Mina Kalantari[SUP] 5 [/SUP], Emily K Silzel[SUP] 2 [/SUP], Algis Jasinskas[SUP] 2 [/SUP], Frank Zaldivar[SUP] 2 6 [/SUP], Sebastian D Schubl[SUP] 7 [/SUP], Philip L Felgner[SUP] 2 [/SUP], Saahir Khan[SUP] 8 [/SUP]
Affiliations
- PMID: 37266444
- PMCID: PMC10229859
- DOI: 10.3389/fimmu.2023.1166261
Introduction: In the context of recurrent surges of SARS-CoV-2 infections, a detailed characterization of antibody persistence over a 6-month period following vaccine booster dose is necessary to crafting effective public health policies on repeat vaccination.
Methods: To characterize the SARS-CoV-2 antibody profile of a healthcare worker population over a 6-month period following mRNA vaccination and booster dose. 323 healthcare workers at an academic medical center in Orange County, California who had completed primary vaccination and booster dose against SARS-CoV-2 were recruited for the study. A total of 690 blood specimens over a 6-month period were collected via finger-stick blood and analyzed for the presence of antibodies against 9 SARS-CoV-2 antigens using a coronavirus antigen microarray.
Results: The primary outcome of this study was the average SARS-CoV-2 antibody level as measured using a novel coronavirus antigen microarray. Additional outcomes measured include levels of antibodies specific to SARS-CoV-2 variants including Delta, Omicron BA.1, and BA.2. We also measured SARS-CoV-2 neutralization capacity for a subset of the population to confirm correlation with antibody levels. Although antibodies against SARS-CoV-2 wane throughout the 6-month period following a booster dose, antibody levels remain higher than pre-boost levels. However, a booster dose of vaccine based on the original Wuhan strain generates approximately 3-fold lower antibody reactivity against Omicron variants BA.1 and BA.2 as compared to the vaccine strain. Despite waning antibody levels, neutralization activity against the vaccine strain is maintained throughout the 6-month period.
Discussion: In the context of recurrent surges of SARS-CoV-2 infections, our data indicate that breakthrough infections are likely driven by novel variants with different antibody specificity and not by time since last dose of vaccination, indicating that development of vaccinations specific to these novel variants is necessary to prevent future surges of SARS-CoV-2 infections.
Keywords: SARS-CoV-2; healthcare worker (HCW); mRNA; serology; vaccine.